Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6113101 | 0.77 | ELANE (0.42) | ELANEDGAT1HDAC6HDAC1HDAC2 | |
| SCHEMBL9326229 | 0.75 | ELANE (0.41) | ELANEDGAT1HDAC6HDAC1HDAC2 | |
| SCHEMBL28653916 | 0.73 | ELANE (0.39) | ELANEDGAT1HDAC6HDAC1HDAC2 | |
| SCHEMBL29121 | 0.73 | DGAT1 (0.46) | ELANEDGAT1HDAC6HDAC1HDAC2 | |
| SCHEMBL8503697 | 0.71 | ELANE (0.38) | ELANEDGAT1HDAC6HDAC1HDAC2 | |
| SCHEMBL77788 | 0.71 | DGAT1 (0.40) | ELANEDGAT1 | |
| SCHEMBL796349 | 0.71 | DGAT1 (0.40) | ELANEDGAT1 | |
| SCHEMBL191648 | 0.71 | DGAT1 (0.40) | ELANEDGAT1 | |
| SCHEMBL77789 | 0.71 | DGAT1 (0.40) | ELANEDGAT1 | |
| Fluoride SCHEMBL2692246 | 0.70 | DGAT1 (0.43) | ELANEDGAT1HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943189-B2 | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG CO-A reductase inhibitors | G.D. SEARLE & CO. (US) | 2005-09-13 | — | — | US | disclosed |
| EP-0888333-B1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | SEARLE LLC (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040204478-A1 | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | G.D. SEARLE & COMPANY | 2004-10-14 | — | — | US | disclosed |
| EP-1466911-A2 | Preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | G.D. Searle & Co. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-6784201-B2 | FOR PROPHYLAXIS AND TREATMENT OF HYPERLIPIDEMIC CONDITIONS SUCH AS THOSE ASSOCIATED WITH ATHEROSCLEROSIS OR HYPERCHOLESTEROLEMIA | G.D. SEARLE & COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040157915-A1 | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors | G.D. SEARLE & CO. (US) | 2004-08-12 | — | — | US | disclosed |
| EP-1440972-A1 | Novel benzothiepines having pharmaceutical activity. | G.D. Searle & Co. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20040014803-A1 | Novel benzothiepines having activity as inhibitors of lleal bile acid transport and taurocholate uptake | G.D. SEARLE & CO. (US) | 2004-01-22 | — | — | US | disclosed |
| EP-1091953-B1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | SEARLE & CO (US) | 2003-12-10 | — | — | EP | disclosed |
| US-6642268-B2 | Treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals. | G.D. SEARLE & CO. | 2003-11-04 | — | — | US | disclosed |
| US-20030171426-A1 | Combination therapy employing ileal bile acid transport inhibiting benzothiepiens and HMG Co-A reductase inhibitors | G.D. SEARLE & CO. (US) | 2003-09-11 | — | — | US | disclosed |
| US-6420417-B1 | TREATMENT OF HYPERLIPIDEMIC CONDITIONS SUCH AS THOSE ASSOCIATED WITH ATHEROSCLEROSIS OR HYPERCHOLESTEROLEMIA IN MAMMALS | G. D. SEARLE & CO. | 2002-07-16 | — | — | US | disclosed |
| US-6387924-B2 | ATHEROSCLEROSIS; ANTICHOLESTEROL AGENTS; ANTILIPIDEMIC AGENTS | G.D. SEARLE & CO. | 2002-05-14 | — | — | US | disclosed |
| US-20020013476-A1 | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | G.D. SEARLE & CO. | 2002-01-31 | — | — | US | disclosed |
| US-6268392-B1 | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors | G. D. SEARLE & CO. | 2001-07-31 | — | — | US | disclosed |
| US-6262277-B1 | IN MEDICINE FOR PROPHYLAXIS AND THERAPY OF HYPERLIPIDEMIC CONDITIONS SUCH AS THOSE ASSOCIATED WITH ATHEROSCLEROSIS OR HYPERCHOLESTEROLEMIA, IN MAMMALS | G.D. SEARLE AND COMPANY | 2001-07-17 | — | — | US | disclosed |
| EP-0781278-B1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | MONSANTO CO (US) | 2001-03-14 | — | — | EP | disclosed |
| US-6107494-A | FOR TREATMENT OF HYPERLIPIDEMIC CONDITIONS SUCH AS THOSE ASSOCIATED WITH ATHEROSCLEROSIS OR HYPERCHOLESTEROLEMIA, IN MAMMALS | G.D. SEARLE AND COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| US-5994391-A | HYPERLIPEMIC AGENTS; ANTICHOLESTEROL AGENTS | G.D. SEARLE AND COMPANY (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1996008484-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | MONSANTO COMPANY (US) | 1996-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013476-A1 | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | SLC10A2, SLC10A1, ABCB11 | ELANE 3186/4885DGAT1 389/4885HDAC6 2078/4885 |
| US-20040204478-A1 | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | SLC10A2, SLC10A1, ABCB11 | ELANE 3186/4885DGAT1 389/4885HDAC6 2078/4885 |
| US-20040157915-A1 | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors | SLC10A2, SLC10A1, HMGCR | ELANE 3065/4885DGAT1 547/4885HDAC6 2797/4885 |
| US-20030171426-A1 | Combination therapy employing ileal bile acid transport inhibiting benzothiepiens and HMG Co-A reductase inhibitors | SLC10A2, SLC10A1, HMGCR | ELANE 2873/4885DGAT1 393/4885HDAC6 2495/4885 |
| US-20040014803-A1 | Novel benzothiepines having activity as inhibitors of lleal bile acid transport and taurocholate uptake | SLC10A1, SLC10A2, NR1H4 | ELANE 1164/4885DGAT1 762/4885HDAC6 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.